Company intelligence / Profile preview

Roxane Laboratories

Columbus, Ohio, United Stateshikma.com ↗

Ownership: Private
Employees: ~1360
Development stage: Commercial

Overview

Prior to its acquisition by Hikma Pharmaceuticals in 2016, Roxane Laboratories was a leading US specialty generics company with 88 marketed products and a robust pipeline of 89 R&D projects. Its strengths included immediate-release solids as well as nasal spray, liquid and sub-lingual tablet products. It had particular expertise in technically complex formulations and high-potency compounds[2][5][6].

Therapeutic areas: OncologyPulmonologyNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

1 asset

metoclopramide

Approved

Partnerships

Boehringer IngelheimPfizer

Beyond the preview

Go deeper on Roxane Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Roxane Laboratories.

Explore the full profile